What are the real alternatives to Mounjaro for weight loss in the UK?

The decision starts with what's actually licensed for weight loss here

Before comparing, it helps to be clear about what counts as a genuine alternative. Ozempic is semaglutide, yes, but it is licensed for type 2 diabetes, not weight management, prescribing it for weight loss would be off-label. Rybelsus (oral semaglutide 3/7/14mg) is the same story. Neither belongs in a straightforward list of alternatives for someone seeking weight-loss treatment.

The medicines that are licensed for weight management in UK adults are Mounjaro (tirzepatide), Wegovy injection (semaglutide) and (since the MHRA approved it on 11 June 2026) Wegovy tablets. The UK was the first country in Europe to approve that oral option. These three are the realistic starting point for any conversation about alternatives.

It is also worth noting that over-the-counter alternatives do not exist for this class of medicine. GLP-1 receptor agonists and dual agonists require a prescription because they act on hormone pathways that need clinical oversight, that is not a bureaucratic detail, it is a clinical one. Orlistat is available without a prescription at lower doses, but it works via a completely different mechanism and produces meaningfully smaller average reductions.

How the mechanisms differ, and why that matters for your choice

Mounjaro activates two receptors: GIP and GLP-1. Wegovy (injection and tablet) activates GLP-1 only. Both pathways slow gastric emptying and reduce appetite, but the dual action in tirzepatide appears to produce a more pronounced effect on food intake and metabolic markers for many people, as the NHS explains in its tirzepatide guidance.

In the SURMOUNT-5 trial (a head-to-head comparison published in the New England Journal of Medicine in 2025) tirzepatide produced greater average weight loss than semaglutide 2.4mg over 72 weeks in adults with obesity and no diabetes. NICE's appraisal of tirzepatide (TA1026) references this comparison in its committee discussion. Wegovy at the newer 7.2mg maintenance dose, approved in January 2026 and now available as a dedicated single-dose pen, narrows that gap: trials reported roughly 20.7% average loss at that higher dose. Semaglutide at 2.4mg produced around 15% in STEP 1 at 68 weeks; tirzepatide at 15mg produced around 20–21% in SURMOUNT-1.

For people weighing up tirzepatide against semaglutide-based alternatives, those numbers are a starting point, not a verdict. Individual response varies considerably, and the medicine that works best for one person may not be the best fit for another.

Practical factors: injections, tablets and how the routes differ day to day

One of the most common questions our prescribers hear is whether there is a tablet rather than an injection. There now is. The Wegovy tablet is taken once daily, first thing in the morning before food or drink, with a small amount of plain water. It needs no refrigeration, which matters if you travel regularly or simply find the fridge routine a nuisance. The 25mg maintenance dose is reached gradually over several months, starting at 1.5mg.

Both injection options (Mounjaro's KwikPen and the Wegovy pre-filled pen) are once weekly and subcutaneous. Many people find a weekly injection far less intrusive than a daily tablet; others feel the opposite. Neither preference is wrong. The injection pens are stored in the fridge; the tablet sits in a cupboard. That everyday difference is worth factoring in before you decide.

Cost is another practical consideration. The price of private weight-loss treatment varies by medicine, dose and provider. A useful reference: following Eli Lilly's list price increase in September 2025, Mounjaro's highest-dose pen rose to around £330 at list price, with typical private market prices ranging roughly £149–£375 per month by dose. You can find a fuller breakdown on the Mounjaro cost page. The right question, though, is not which is cheapest, it is which is clinically appropriate for you, sourced through a GPhC-registered pharmacy you can verify.

Which alternative is right for you, and how a prescriber decides

No content page can answer that question, and any that claims to is oversimplifying. Your eligibility for Mounjaro or any of its alternatives depends on your BMI, any weight-related health conditions, your medication history, contraindications and other clinical factors. Whether an alternative is appropriate in a given situation (for example, if you have been on Mounjaro and it is not suiting you, or if you cannot manage injections) is a clinical decision, made by a prescriber who has reviewed your full history.

At nume, every consultation is read by a GPhC-registered Independent Prescriber on the same day. They review your answers, your current health picture and any evidence you supply, and they make the clinical call. There is no algorithm making that decision. If you are curious about how our clinical team approaches these choices, our clinical team profile gives some context on who is doing the reviewing.

The broader picture of what weight-loss treatment looks like (including how Mounjaro, Wegovy and the new Wegovy tablet compare across different situations) is covered on our weight-loss treatment overview. If you are ready to find out which option a prescriber would consider for you, you can check your eligibility below.